KLRA (Kailera Therapeutics) PB Ratio: (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KLRA Kailera Therapeutics Inc KLRA
11 GF Score
Price $17.32
! 1 Warning Sign
View Full Analysis

What is Kailera Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-04), Kailera Therapeutics's share price is $17.32. Kailera Therapeutics's Book Value per Share for the quarter that ended in Dec. 2025 was $-3.02. Hence, Kailera Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Kailera Therapeutics's PB Ratio or its related term are showing as below:

KLRA's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.765
* Ranked among companies with meaningful PB Ratio only.

Back to Basics: PB Ratio

Kailera Therapeutics  (NAS:KLRA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.

Kailera Therapeutics PB Ratio Related Terms

Kailera Therapeutics PB Ratio Historical Data

* Premium members only.

The historical data trend for Kailera Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kailera Therapeutics PB Ratio Chart

Kailera Therapeutics Annual Data
Trend Dec24 Dec25
PB Ratio
0.00 0.00

Kailera Therapeutics Semi-Annual Data
Dec24 Dec25
PB Ratio 0.00 0.00

KLRA vs VCEL, NUVB, IOVA: PB Ratio Comparison

For the Biotechnology subindustry, Kailera Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kailera Therapeutics PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kailera Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Kailera Therapeutics's PB Ratio falls into.


KLRA
11GF Score
Kailera Therapeutics Inc KLRA
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kailera Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Kailera Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2025)
=17.32/-3.022
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PB Ratio=Market Cap /(Total Stockholders Equity-Preferred Stock)

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Kailera Therapeutics Business Description

Address 180 Third Avenue, 4th Floor, Waltham, MA, USA, 02451
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
11GF Score

Get the complete analysis for KLRA

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.32
Price